How to make drugs more affordable without stifling beneficial innovation and competition
CRITICS OF THE U.S. PHARMACEUTICAL INDUSTRY allege that U.S. consumers are subsidizing the rest of the world because
A related allegation is that in the United States there is cost shifting to cash-paying, retail customers-including many of the elderly-who pay excessive prices because of discounts to managed-care organizations and government purchasers. Then there is the general belief that drug prices are simply "too high"-that the pharmaceutical industry is making excessive profits.
These bits of conventional wisdom may be conventional but they are not wisdom. Facts and logic will lead us to these conclusions:
* Cross-national and domestic price differences are smaller than has been alleged.